Comparison of Brain Gadolinium Deposition Between Linear and Macrocyclic Gadolinium-Based Contrast Agents (GBCAs): a Prospective, Randomized, Controlled Study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039419

Enrollment

Unknown

Registered

2020-10-27

Start date

2020-10-30

Completion date

Unknown

Last updated

2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cancer

Interventions

experimental group:Macrocyclic gadolinium-based contrast agents

control group:Linear gadolinium-based contrast agents

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with liver cancer; 2. Can be resected; 3. With no history of gadolinium MRI scanning.

Exclusion criteria

Exclusion criteria: 1. Younger than 18-year; 2. With lesion in the brain; 3. Contraindications to MRI or gadolinium agent.

Design outcomes

Primary

Measure	Time frame
T1 signal of basal ganglia;Adverse events;	—

Countries

China

Contacts

Public ContactMeng-Su Zeng

Zhongshan Hospital Fudan University

zeng.mengsu@zs-hospital.sh.cn+86 13501922963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026